drugset
drugset / Trial / NCT05295212

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

NCT05295212 ↗

Phase 2 Recruiting 120 enrolled Hunan Province Tumor Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.

Timeline

Start
2023-02-01
Primary completion
2024-12-01
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Background Carboplatin Small molecule — —
Background Paclitaxel Small molecule 260 mg/m2 —
Background Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma